Kristi Riddle
Family · Jackson, TNNPI 1568452837
Payments from drug & device makers
Across 685 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$1K
- Novartis$1K
- Biogen$558
- Bristol Myers Squibb$556
- SK Life Science, Inc.$542
- plus $5K from 31 others
What the payments were for
- Food & beverage$11,256100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 155 | $2,127 |
| Pfizer | 135 | $1,367 |
| Novartis | 76 | $1,310 |
| Biogen | 26 | $558 |
| Bristol Myers Squibb | 25 | $556 |
| SK Life Science, Inc. | 24 | $542 |
| Amneal Pharmaceuticals LLC | 27 | $511 |
| UCB, Inc. | 15 | $466 |
| AstraZeneca(2 entities) | 21 | $429 |
| Biohaven Pharmaceuticals, Inc. | 23 | $407 |
| Eisai Inc. | 18 | $350 |
| Genentech USA, Inc. | 17 | $277 |
| Lundbeck LLC | 16 | $274 |
| Argenx US, Inc. | 12 | $263 |
| Teva Pharmaceuticals USA, Inc. | 14 | $260 |
| Biohaven Pharmaceutical Holding Company Ltd. | 16 | $245 |
| Otsuka America Pharmaceutical, Inc. | 13 | $240 |
| Neurocrine Biosciences, Inc. | 7 | $157 |
| Acadia Pharmaceuticals Inc | 8 | $152 |
| EMD Serono, Inc. | 5 | $111 |
| Axsome Therapeutics, Inc. | 4 | $104 |
| TG Therapeutics, Inc. | 3 | $97 |
| Amgen(2 entities) | 3 | $52 |
| CSL Behring | 2 | $46 |
| Merz Pharmaceuticals, LLC | 1 | $46 |
| Neurelis, Inc. | 2 | $45 |
| Adamas Pharmaceuticals, Inc. | 2 | $38 |
| Johnson & Johnson | 3 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Avion Pharmaceuticals | 2 | $33 |
| Lilly USA, LLC | 2 | $31 |
| GRT US Holding, Inc. | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Tanabe Pharma America, Inc. | 1 | $13 |
| Banner Life Sciences, LLC | 1 | $13 |
| Sanofi | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,256 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 151 | $221,587 |
| TecfideraDimethyl Fumarate | 13 | $115,830 |
| VumerityDiroximel Fumarate | 12 | $106,045 |
| UbrelvyUbrogepant | 68 | $101,727 |
| Emgality PenGalcanezumab-Gnlm | 119 | $100,551 |
| QuliptaAtogepant | 77 | $91,775 |
| Aimovig AutoinjectorErenumab-Aooe | 103 | $83,968 |
| CopaxoneGlatiramer Acetate | 14 | $80,337 |
| Dimethyl Fumarate | 19 | $54,197 |
| AptiomEslicarbazepine Acetate | 40 | $52,535 |
| VimpatLacosamide | 28 | $23,033 |
| Dalfampridine ErDalfampridine | 23 | $18,635 |
| RexultiBrexpiprazole | 13 | $18,343 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 24 | $16,930 |
| GlatopaGlatiramer Acetate | 11 | $16,458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera, Vumerity | $558 | $221,87525 claims |
| PfizerNurtec Odt | $1,367 | $221,587151 claims |
| AbbVieUbrelvy, Qulipta | $2,127 | $193,502145 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $260 | $80,33714 claims |
| UCB, Inc.Vimpat | $466 | $23,03328 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $240 | $18,34313 claims |
| Eisai Inc.Fycompa | $350 | $15,85819 claims |
| Amneal Pharmaceuticals LLCRytary | $511 | $13,27916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Jackson
- Anahita AndersonJackson$85K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.